164 related articles for article (PubMed ID: 17414461)
1. A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer.
Chow LW; Yip AY; Lang BH
Am J Clin Oncol; 2007 Apr; 30(2):133-8. PubMed ID: 17414461
[TBL] [Abstract][Full Text] [Related]
2. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
Ardavanis A; Mavroudis D; Kalbakis K; Malamos N; Syrigos K; Vamvakas L; Kotsakis A; Kentepozidis N; Kouroussis C; Agelaki S; Georgoulias V;
Cancer Chemother Pharmacol; 2006 Dec; 58(6):742-8. PubMed ID: 16718470
[TBL] [Abstract][Full Text] [Related]
3. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.
Addeo R; Faiola V; Guarrasi R; Montella L; Vincenzi B; Capasso E; Cennamo G; Rotundo MS; Tagliaferri P; Caraglia M; Del Prete S
Cancer Chemother Pharmacol; 2008 Jul; 62(2):285-92. PubMed ID: 17922275
[TBL] [Abstract][Full Text] [Related]
4. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.
Mlineritsch B; Schabel-Moser R; Andel J; Fridrik M; Moik M; Mayer P; Russ G; Rass C; Greil R;
Onkologie; 2009 Feb; 32(1-2):18-24. PubMed ID: 19209014
[TBL] [Abstract][Full Text] [Related]
5. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
6. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu-negative metastatic breast cancer.
Farhat FS; Temraz S; Kattan J; Ibrahim K; Bitar N; Haddad N; Jalloul R; Hatoum HA; Nsouli G; Shamseddine AI
Clin Breast Cancer; 2011 Dec; 11(6):384-9. PubMed ID: 21993011
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.
Delozier T; Guastalla JP; Yovine A; Levy C; Chollet P; Mousseau M; Delva R; Coeffic D; Vannetzel JM; Zazzi ES; Brienza S; Cvitkovic E
Anticancer Drugs; 2006 Oct; 17(9):1067-73. PubMed ID: 17001180
[TBL] [Abstract][Full Text] [Related]
9. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.
Alba E; Ruiz-Borrego M; Margelí M; Rodríguez-Lescure A; Sánchez-Rovira P; Ruiz A; Mel-Lorenzo JR; Ramos-Vázquez M; Ribelles N; Calvo E; Casado A; Márquez A; Vicente D; García-Sáenz JA; Martín M
Breast Cancer Res Treat; 2010 Jul; 122(1):169-76. PubMed ID: 20361253
[TBL] [Abstract][Full Text] [Related]
10. Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model.
Dranitsaris G; Rayson D; Vincent M; Chang J; Gelmon K; Sandor D; Reardon G
Am J Clin Oncol; 2008 Aug; 31(4):369-74. PubMed ID: 18845996
[TBL] [Abstract][Full Text] [Related]
11. Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer.
Bourgeois H; Ferru A; Lortholary A; Delozier T; Boisdron-Celle M; Abadie-Lacourtoisie S; Joly F; Chieze S; Chabrun V; Gamelin E; Tourani JM
Am J Clin Oncol; 2006 Jun; 29(3):267-75. PubMed ID: 16755180
[TBL] [Abstract][Full Text] [Related]
12. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
13. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
[TBL] [Abstract][Full Text] [Related]
14. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
[TBL] [Abstract][Full Text] [Related]
15. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
[TBL] [Abstract][Full Text] [Related]
17. Liposomal pegylated doxorubicin and oxaliplatin as salvage chemotherapy in patients with metastatic gastric cancer treated earlier.
Recchia F; Candeloro G; Guerriero G; Piazze J; Desideri G; Necozione S; Rea S
Anticancer Drugs; 2010 Jun; 21(5):559-64. PubMed ID: 20308874
[TBL] [Abstract][Full Text] [Related]
18. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
[TBL] [Abstract][Full Text] [Related]
19. Combination of vinorelbine + doxorubicin in advanced breast cancer.
Lorvidhaya V; Kamnerdsupaphon P; Chitapanarux I; Srisukho S; Trakultivakorn H; Sumitsawan S; Sukthomya V; Tonusin A
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1131-8. PubMed ID: 12938268
[TBL] [Abstract][Full Text] [Related]
20. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
Gorumlu G; Kucukzeybek Y; Kemal-Gul M; Karaca B; Cosan-Terek M; Karabulut B; Sanli UA; Akman L; Ozsaran A; Dikmen Y; Uslu R
J BUON; 2008; 13(3):349-52. PubMed ID: 18979548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]